UA85996C2 - Слитый антикоагулянтный белок тромбомодулина, который обеспечивает направленное перенесение к тканевому фактору - Google Patents

Слитый антикоагулянтный белок тромбомодулина, который обеспечивает направленное перенесение к тканевому фактору

Info

Publication number
UA85996C2
UA85996C2 UA20041109788A UA20041109788A UA85996C2 UA 85996 C2 UA85996 C2 UA 85996C2 UA 20041109788 A UA20041109788 A UA 20041109788A UA 20041109788 A UA20041109788 A UA 20041109788A UA 85996 C2 UA85996 C2 UA 85996C2
Authority
UA
Ukraine
Prior art keywords
domain
tissue factor
fusion proteins
anticoagulants
thrombomodulin
Prior art date
Application number
UA20041109788A
Other languages
English (en)
Ukrainian (uk)
Inventor
Дэвид Лайт
Кирк Маклин
Original Assignee
Шеринг Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29401364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA85996(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Шеринг Акциенгезельшафт filed Critical Шеринг Акциенгезельшафт
Publication of UA85996C2 publication Critical patent/UA85996C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/7455—Thrombomodulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Данное изобретение касается новых слитых антикоагулянтных белков, которые включают белок, обеспечивающий направленное перенесение и взаимодействует с тканевым фактором (TF) или комплексом фактора VIIa/TF, а именно связывает TF или комплекс VIIa/TF, и какой функционально связан с тромбомодулиновым (ТМ) доменом EGF456 или его аналогами, и с доменом ТМ, который включает междоменную петлю между EGF3 и EGF4. Слитый белок связывается в участке повреждения и предотвращает инициацию тромбоза. Слитый белок может применяться для терапии разных тромбозных состояний, включая тромбоз глубоких вен, коагулопатию потребления и острый коронарный синдром.
UA20041109788A 2002-05-01 2003-04-30 Слитый антикоагулянтный белок тромбомодулина, который обеспечивает направленное перенесение к тканевому фактору UA85996C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37656602P 2002-05-01 2002-05-01

Publications (1)

Publication Number Publication Date
UA85996C2 true UA85996C2 (ru) 2009-03-25

Family

ID=29401364

Family Applications (2)

Application Number Title Priority Date Filing Date
UA20041109787A UA81114C2 (en) 2002-05-01 2003-04-30 Novel antibodies to tissue factor as anticoagulants
UA20041109788A UA85996C2 (ru) 2002-05-01 2003-04-30 Слитый антикоагулянтный белок тромбомодулина, который обеспечивает направленное перенесение к тканевому фактору

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UA20041109787A UA81114C2 (en) 2002-05-01 2003-04-30 Novel antibodies to tissue factor as anticoagulants

Country Status (29)

Country Link
US (3) US7250168B2 (ru)
EP (2) EP1503785B1 (ru)
JP (2) JP4567437B2 (ru)
KR (2) KR101013697B1 (ru)
CN (2) CN100563709C (ru)
AR (1) AR039515A1 (ru)
AT (2) ATE427121T1 (ru)
AU (2) AU2003225255B2 (ru)
BR (2) BR0304659A (ru)
CA (2) CA2483910A1 (ru)
CR (1) CR7584A (ru)
DE (2) DE60334538D1 (ru)
DK (2) DK1549341T3 (ru)
EC (2) ECSP045468A (ru)
ES (2) ES2354419T3 (ru)
HK (1) HK1080372A1 (ru)
IL (3) IL164733A0 (ru)
MX (2) MXPA04010851A (ru)
NO (2) NO20035848L (ru)
NZ (2) NZ536243A (ru)
PE (1) PE20040597A1 (ru)
PL (2) PL373945A1 (ru)
PT (2) PT1549341E (ru)
RS (2) RS102404A (ru)
RU (2) RU2345789C2 (ru)
TW (1) TWI343388B (ru)
UA (2) UA81114C2 (ru)
WO (2) WO2003092602A2 (ru)
ZA (2) ZA200409694B (ru)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE455852T1 (de) * 1999-06-02 2010-02-15 Chugai Pharmaceutical Co Ltd Neues hämopoietin rezeptorprotein nr10
WO2001023556A1 (en) * 1999-09-27 2001-04-05 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, nr12
US7312325B2 (en) 2000-09-26 2007-12-25 Duke University RNA aptamers and methods for identifying the same
US7579000B2 (en) * 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
JP4567437B2 (ja) * 2002-05-01 2010-10-20 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 抗凝固剤としての新規組織因子標的化されたトロンボモジュリン融合タンパク質
AU2003256299A1 (en) 2002-07-01 2004-01-19 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
US7425328B2 (en) 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US7833978B2 (en) * 2004-02-20 2010-11-16 Emory University Thrombomodulin derivatives and conjugates
PL1745062T3 (pl) 2004-04-22 2014-10-31 Regado Biosciences Inc Ulepszone modulatory czynników krzepnięcia
CA2609262A1 (en) * 2005-06-03 2006-12-07 Mochida Pharmaceutical Co., Ltd. Anti-cd14 antibody fusion protein
WO2008039206A2 (en) * 2005-10-05 2008-04-03 The Trustees Of The University Of Pennsylvania Fusion proteins for inhibition and dissolution of coagulation
US20110040073A1 (en) * 2006-04-07 2011-02-17 Novo Nordisk Healthcare A/G Covalent Factor VII-Tissue Factor Complex
WO2007142325A1 (ja) 2006-06-08 2007-12-13 Chugai Seiyaku Kabushiki Kaisha 炎症性疾患の予防または治療剤
JP5579385B2 (ja) * 2006-10-06 2014-08-27 旭化成ファーマ株式会社 播種性血管内血液凝固症候群の治療及び／又は改善剤
WO2008121814A1 (en) * 2007-03-28 2008-10-09 Ats Medical, Inc. Method for inhibiting platelet interaction with biomaterial surfaces
EP2195343A2 (en) * 2007-09-20 2010-06-16 Bracco Imaging S.p.A Method for the preparation of new oligoclonal antibodies
CN104162155A (zh) 2007-12-05 2014-11-26 中外制药株式会社 搔痒症治疗药
US8333973B2 (en) * 2008-01-02 2012-12-18 The Trustees Of The University Of Pennsylvania Targeting recombinant therapeutics to circulating red blood cells
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
EP2321338A1 (en) * 2008-08-14 2011-05-18 Merck Sharp & Dohme Corp. Methods for purifying antibodies using protein a affinity chromatography
WO2010045518A1 (en) * 2008-10-16 2010-04-22 The Trustees Of The University Of Pennsylvania Compositions containing thrombomodulin domains and uses thereof
US20120165244A1 (en) * 2008-10-30 2012-06-28 Hua-Lin Wu Methods for binding lewis y antigen
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
EP2230251A1 (en) * 2009-03-19 2010-09-22 Bracco Imaging S.p.A Antibodies specifically active in the coronary plaque and method for their identification
CA2771328A1 (en) * 2009-08-28 2011-03-03 Bayer Healthcare Llc Cofactors for thrombin activation of factor vii and uses thereof
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
RU2585231C2 (ru) 2010-06-04 2016-05-27 Ск Кемикалз Ко., Лтд. Слитый белок, обладающий активностью фактора vii
JP6055404B2 (ja) 2010-06-15 2016-12-27 ゲンマブ エー／エス 組織因子に対するヒト抗体薬物結合体
US9150844B2 (en) * 2010-08-05 2015-10-06 Neeraj Maheshwari Protein fusion constructs possessing thrombolytic and anticoagulant properties
RU2445365C1 (ru) * 2010-11-03 2012-03-20 Общество с ограниченной ответственностью "Инновационный Центр "Новые Технологии и Материалы" (ООО "ИЦ Новтехмат") Штамм гибридных культивируемых клеток mus musculus - продуцент моноклональных антител, специфичных к протеину с человека (варианты)
KR20170134748A (ko) 2015-04-14 2017-12-06 추가이 세이야쿠 가부시키가이샤 Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물
WO2016176440A2 (en) * 2015-04-28 2016-11-03 Saint Louis University Thrombin-thrombomodulin fusion proteins as protein c activators
US11085031B2 (en) 2016-04-28 2021-08-10 Saint Louis University Thrombin-thrombomodulin fusion proteins as a powerful anticoagulant
AR110079A1 (es) * 2016-11-16 2019-02-20 Bayer Healthcare Llc Factor viii direccionado a los glóbulos rojos y método para su uso
BR102017005783A2 (pt) * 2017-03-21 2018-10-02 Fund Butantan processo de obtenção de esculptina e seus fragmentos, esculptina recombinante e seus usos
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
WO2019217455A1 (en) 2018-05-07 2019-11-14 Genmab A/S Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
WO2020070237A1 (en) * 2018-10-04 2020-04-09 Thrombosis And Coagulation Ab Method for the determination of protein s levels
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
CN114728064B (zh) 2019-11-20 2025-05-06 中外制药株式会社 含抗体制剂
CN114686443B (zh) * 2020-12-31 2023-11-03 广州万孚生物技术股份有限公司 杂交瘤细胞、抗血栓调节蛋白单克隆抗体及其制备方法和应用
CN114686444B (zh) * 2020-12-31 2024-05-31 广州万孚生物技术股份有限公司 杂交瘤细胞、抗血栓调节蛋白单克隆抗体及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
ZA862768B (en) * 1985-04-17 1986-12-30 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5589173A (en) 1986-11-04 1996-12-31 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
US5437864A (en) * 1987-03-31 1995-08-01 The Scripps Research Institute Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US4912207A (en) 1987-05-06 1990-03-27 Washington University DNA clone of human thrombomodulin and portions thereof
DK299087D0 (da) 1987-06-12 1987-06-12 Novo Industri As Proteins and derivatives thereof
US5298599A (en) * 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
CA2046906A1 (en) * 1989-02-17 1990-08-18 Michael J. Morser Soluble analogs of thrombomodulin
US5466668A (en) 1989-04-28 1995-11-14 Schering Aktiengesellschaft Superior thrombomodulin analogs for pharmaceutical use
US6063763A (en) 1989-04-28 2000-05-16 Schering Aktiengesellschaft Protease-resistant thrombomodulin analogs
US5256770A (en) 1990-04-09 1993-10-26 Schering Ag Oxidation resistant thrombomodulin analogs
KR930008093B1 (ko) 1990-08-03 1993-08-25 아사히가세이고오교 가부시끼가이샤 신규 폴리펩티드 및 이를 유효성분으로 하는 의약조성물
US5843442A (en) * 1990-10-22 1998-12-01 Corvas International, Inc. Blood coagulation protein antagonists and uses therefor
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
JPH0578397A (ja) * 1991-01-29 1993-03-30 Sumitomo Pharmaceut Co Ltd 血栓溶解タンパク質
JPH06133780A (ja) * 1992-10-23 1994-05-17 Sumitomo Pharmaceut Co Ltd 新規なｔ−ＰＡ改変体
US5916874A (en) 1994-04-20 1999-06-29 Asahi Kasei Kogyo Kabushiki Kaisha Method for treating liver injury
US5736364A (en) * 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
US5986065A (en) 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US6677436B1 (en) * 1998-04-03 2004-01-13 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody
EP1263960A2 (en) * 2000-03-16 2002-12-11 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
US6632791B1 (en) * 2000-06-21 2003-10-14 Schering Aktiengesellschaft Thrombomodulin analogs for pharmaceutical use
TWI338009B (en) * 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
EP1465998A2 (en) 2002-01-08 2004-10-13 Bayer HealthCare AG Single nucleotide polymorphisms predicting cardiovascular disease and medication efficacy
JP4567437B2 (ja) 2002-05-01 2010-10-20 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 抗凝固剤としての新規組織因子標的化されたトロンボモジュリン融合タンパク質
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants

Also Published As

Publication number Publication date
EP1549341A4 (en) 2006-10-18
MXPA04010795A (es) 2005-03-07
JP4567437B2 (ja) 2010-10-20
DK1503785T3 (da) 2011-02-07
MXPA04010851A (es) 2005-02-14
NO20035849L (no) 2004-02-27
EP1503785A4 (en) 2007-02-14
US7250168B2 (en) 2007-07-31
ES2354419T3 (es) 2011-03-14
PT1503785E (pt) 2011-01-17
WO2003093422A2 (en) 2003-11-13
PL373945A1 (en) 2005-09-19
EP1503785B1 (en) 2010-10-13
JP2005538046A (ja) 2005-12-15
ES2323056T3 (es) 2009-07-06
RU2345789C2 (ru) 2009-02-10
US7622457B2 (en) 2009-11-24
US20080020965A1 (en) 2008-01-24
ATE427121T1 (de) 2009-04-15
JP2005532045A (ja) 2005-10-27
IL164732A0 (en) 2005-12-18
HK1080372A1 (zh) 2006-04-28
ECSP045468A (es) 2005-01-28
ATE484524T1 (de) 2010-10-15
US20040063632A1 (en) 2004-04-01
WO2003092602A3 (en) 2004-08-26
UA81114C2 (en) 2007-12-10
TW200307043A (en) 2003-12-01
US7622122B2 (en) 2009-11-24
DE60334538D1 (de) 2010-11-25
IL164733A0 (en) 2005-12-18
ZA200409692B (en) 2006-07-26
CR7584A (es) 2006-05-30
CN100412090C (zh) 2008-08-20
PE20040597A1 (es) 2004-10-06
PL373960A1 (en) 2005-09-19
RU2004135306A (ru) 2005-07-10
CN1665534A (zh) 2005-09-07
PL210582B1 (pl) 2012-02-29
CA2483910A1 (en) 2003-11-13
NZ536242A (en) 2006-04-28
EP1549341B1 (en) 2009-04-01
NO20035848L (no) 2004-02-27
WO2003093422A3 (en) 2004-07-15
IL164733A (en) 2011-05-31
DE60326970D1 (de) 2009-05-14
DK1549341T3 (da) 2009-07-06
CN100563709C (zh) 2009-12-02
AR039515A1 (es) 2005-02-23
RS104504A (sr) 2007-02-05
KR101013697B1 (ko) 2011-02-10
PT1549341E (pt) 2009-05-29
RU2320366C2 (ru) 2008-03-27
AU2003225256A1 (en) 2003-11-17
JP4460443B2 (ja) 2010-05-12
EP1503785A2 (en) 2005-02-09
WO2003092602A2 (en) 2003-11-13
TWI343388B (en) 2011-06-11
CA2483909A1 (en) 2003-11-13
AU2003225255B2 (en) 2008-07-31
RS102404A (sr) 2006-12-15
AU2003225256B2 (en) 2009-06-04
KR20050045945A (ko) 2005-05-17
NZ536243A (en) 2006-06-30
EP1549341A2 (en) 2005-07-06
AU2003225255A1 (en) 2003-11-17
ZA200409694B (en) 2006-02-22
CN1665526A (zh) 2005-09-07
BR0304660A (pt) 2005-06-07
US20080019985A1 (en) 2008-01-24
KR20050045944A (ko) 2005-05-17
KR101080587B1 (ko) 2011-11-04
BR0304659A (pt) 2004-09-21
ECSP045467A (es) 2005-01-28
RU2004135308A (ru) 2005-08-10

Similar Documents

Publication Publication Date Title
UA85996C2 (ru) Слитый антикоагулянтный белок тромбомодулина, который обеспечивает направленное перенесение к тканевому фактору
ES2116325T3 (es) Nuevos inhibidores de la trombina.
EP1385864A4 (en) VASCULAR ENDOTHEL GROWTH FACTOR 2
PT1187918E (pt) Antagonistas de tek
WO2003037911A3 (en) Antibodies for inhibiting blood coagulation and methods of use thereof
WO2002083849A3 (en) Vascular endothelial growth factor 2
MX9606386A (es) Agentes que afectan la hemostasis trombotica.
EP1100535A4 (en) Targeting pharmaceutical agents to injured tissues
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
NO20033839D0 (no) Inhibitorer av transplantatavvisning
DK1974615T3 (da) Proteingeldannelse
DE69831566D1 (de) Probucol monoester zur behandlung von kreislauf- und entzündungserkrankungen
NO20060466L (no) Variable antibodies
MXPA05007689A (es) Tratamiento de enfermedades con agonistas completos del receptor alfa-7 de nach.
CY1112229T1 (el) Αντισωματα κατευθυνομενα εναντι οξειδωμενης απολιποπρωτεϊνης β
WO2005016883A3 (en) Acrylamide derivatives as vla-1 integrin antagonists and uses thereof
DK1194528T3 (da) Monoklonalt antistof mod faktor VII, hvilket antistof selv ved forekomst i molært overskud kun delvist inaktiverer faktor VII, samt fremgangsmåde til produktion af et sådant antistof
DK1109571T3 (da) Fremgangsmåde til behandling af saltafhængig hypertension
EP1487854A4 (en) NOVEL ISOFORMS OF THE VASCULAR ENDOTHELIAL CELL GROWTH INHIBITOR
DE60232733D1 (de) Alternativ gesplicter zirkulierender gewebefaktor
WO2003000183A3 (en) Method of treating atherosclerosis and other inflammatory diseases
EA199800819A1 (ru) Способ лечения биполярного расстройства
WO2005009361A3 (en) Method of treating hit patients with argatroban
FR2843697B1 (fr) L'heterocarpine, une proteine d'origine vegetale aux proprietes anticancereuses
DE50200864D1 (de) Verbundelemente enthaltend bitumen